• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Invitae | Genelex

Invitae | Genelex

Pharmacogenetics Makes Precision Medicine Possible

  • For Patients
    • Conditions
    • Affected Drugs
    • What is PGx?
    • Resources
    • FAQs
  • For Providers
    • Conditions
    • Resources
    • Order Testing Supplies
  • Test Menu
  • Clinical Trials
  • About
    • Lab Accreditations
    • Genelex Team
    • Contact Us
  • Log In

Update on Rifampin and Rifabutin Drug Interactions

Home / Data / Update on Rifampin and Rifabutin Drug Interactions

Genelex Blog

Update on Rifampin and Rifabutin Drug Interactions

COMMENT:: Review of this area is important since in many parts of the world, rifampin is the only drug available for the treatment of TB. There are some notable problems in this review. The protease inhibitors and rifampin are reviewed from the point of view of the effect on the PIs, but the effect of the PIs on rifampin is not considered. Several PIs increase rifampin levels and therefore cannot be used together. This is not discussed in the article. What is extremely valuable are the tables in the article that summarize clinical points.

 

ABSTRACT:Am J Med Sci. 2008 Feb;335(2):126-136.

Update on Rifampin and Rifabutin Drug Interactions. Baciewicz AM, Chrisman CR, Finch CK, Self TH.

Rifampin is a potent inducer of cytochrome P-450 oxidative enzymes as well as the P-glycoprotein transport system. Several examples of well-documented clinically significant interactions include warfarin, oral contraceptives, cyclosporine, itraconazole, digoxin, verapamil, nifedipine, simvastatin, midazolam, and human immunodeficiency virus-related protease inhibitors. Rifabutin reduces serum concentrations of antiretroviral agents, but less so than rifampin. Examples of clinically relevant interactions demonstrated by recent reports include everolimus, atorvastatin, rosiglitazone/ pioglitazone, celecoxib, clarithromycin, caspofungin, and lorazepam.To avoid a decreased therapeutic response, therapeutic failure, or toxic reactions when rifampin is added to or discontinued from medication regimens, clinicians need to be cognizant of these interactions. Studies and cases of rifampin drug interactions continue to increase rapidly. This review is a timely reminder to clinicians to be vigilant. PMID: 18277121

Genelex Resources

Affected Conditions
Affected Drugs
Info for Providers
Frequently Asked Questions
Contact Genelex
Join Our Mailing List

Footer

CONTACT US

(800) 837-8362
info@genelex.com

3101 Western Ave.
Suite 100
Seattle, WA 98121

HELPFUL INFORMATION

What is PGx?
Test Menu
Conditions
Affected Drugs
FAQs
References

ABOUT GENELEX

Blog
News
Genelex Team
Lab Accreditations
Contact Us
Privacy Practices
Privacy Policy

  • Facebook
  • LinkedIn
  • RSS
  • Twitter
  • YouTube

KEEP IN TOUCH

Stay in the loop with news and updates from Genelex and be among the first to know when new tests become available.